TNG Creative Wins Two Prestigious Awards for an Integrated Marketing Campaign
PRINCETON, N.J., April 5, 2023 (Newswire.com) - TNG Creative, an award-winning, healthcare-focused, boutique consultancy, today announced that it has been awarded the 2023 IAC Award for Best Biotechnology Integrated Ad Campaign for its work on the Oncolyze campaign. Additionally, in late 2022, TNG Creative also won the 2022 MarCom Gold Award for an Integrated Marketing Campaign for the same campaign. With both awards, TNG Creative was recognized for its end-to-end design and development of an integrated campaign to raise awareness about Oncolyze, a biotech developing a disruptive technology for the treatment of cancer.
The campaign, called Invest in Oncolyze, highlighted the company's Regulation A+ funding campaign. Regulation A+ is a type of offering that allows anyone to invest in Oncolyze and receive shares in the company. The Invest in Oncolyze campaign aimed to spread awareness of the company's lead drug candidate, OM-301, among cancer patients, healthcare professionals, and the investment community. It consisted of a stand-alone campaign website separate from the corporate website, a one-page executive summary of the investment opportunity, a pitch deck, a campaign video, and a social media presence. The investment opportunity is being hosted by StartEngine and investments may be made in Oncolyze directly by visiting the StartEngine website. Potential investors can also learn more about the investment opportunity at the Oncolyze website.
"We have been helping biotech startups with investor communications for years, but we have never supported a 'crowdfunding' campaign until now. With Oncolyze deciding to embark on the Reg A+ funding route, it has been interesting to be part of something different. There are a lot of investment opportunities out there, so we wanted to do something special to highlight the excitement around Oncolyze's innovative approach to treating cancer. We want to thank the Association of Marketing and Communication Professionals (AMCP) and the Web Marketing Association (WMA) for recognizing this campaign. We also thank the Oncolyze team for continuing to trust us with their strategic communications," said Mika Stojanovic, Head of Marketing + Creative at TNG Creative, and Managing Partner at The Naissos Group.
In 2020, TNG Creative was awarded the IAC Award for Best Biotechnology Website for its development of the Oncolyze corporate website. According to Alex Stojanovic, Head of Strategy at TNG Creative, the secret of repeat success lies in a small, multidisciplinary, and experienced team that seamlessly integrates strategy, science, and creative. "We're a small consultancy and our entire team is intimately involved with each client. We immerse ourselves completely into each company, their science, their mission, and this clearly leads to great results," Stojanovic added.
The MarCom Awards honor excellence in marketing and communication while recognizing the creativity, hard work, and generosity of industry professionals. Since its inception in 2004, MarCom has evolved into one of the largest and most-respected creative competitions in the world. Each year, about 6,500 print and digital entries are submitted from dozens of countries. MarCom is administered by the AMCP.
Founded by Web Marketing Association (WMA), the IAC is the first and only competition dedicated exclusively to online advertising. The IAC awards cover a variety of industries and online formats including online ad, video, mobile, newsletter, email, and social media. A list of winners can be found on the IAC website.
About TNG Creative
TNG Creative, LLC is an award-winning, healthcare-focused, boutique consultancy that bridges the gaps between strategy, science, and creative for life science companies. Headquartered in Princeton, New Jersey, TNG Creative has client relationships in the U.S., Europe, Asia, and Australia. The company leverages a lean consulting model and brings broad life science experience across therapeutic areas, geographies, and company stages, from early stage biotechs to publicly traded corporations. TNG Creative is a wholly owned subsidiary of The Naissos Group, LLC.
About Oncolyze
Oncolyze is developing a disruptive technology for the treatment of cancer. The company's lead drug candidate, OM-301, targets the cancer cell membrane and causes lysis/necrosis; many antibiotics, such as penicillin, kill bacteria in a similar way. The initial therapeutic target is acute myeloid leukemia (AML). Most AML patients relapse within one year of treatment, as standard therapy does not destroy cancer stem cells. As a result, AML has only a 25% five-year survival rate. In contrast, OM-301 has been shown to destroy leukemic cancer stem cells, and therefore has the potential to disrupt current medical treatment.
You should read the Offering Circular and Risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Source: TNG Creative LLC